|
|
|
|
Learn how an integrated developability and immunosafety toolbox can help de-risk multi-specific antibody development, sharpen candidate selection, and move complex biologics toward the clinic faster.
|
|
|
|
|
Lonza’s Rebecca Michael, Ph.D., answers webinar attendees' questions on how in silico and in vitro tools can help developers both assess and mitigate developability risks.
|
|
|
|
|
Development is long, costly, and risky. Discover how to get the most from early-phase material and align your development and manufacturing path with your IND milestones.
|
|
|
|
|
Standard in vivo toxicology studies may lack clinical relevance when assessing immunogenicity. Get an expert view on early immunosafety challenges and risk mitigation strategies.
|
|
|
